stockportfolio.pro
Stocks / CLDX vs KLRA
CLDX vs KLRA
Celldex Therapeutics, Inc. and Kailera Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Celldex Therapeutics, Inc. (CLDX) | Kailera Therapeutics, Inc. (KLRA) | |
|---|---|---|
| Market cap | $2.3B | $2.6B |
| Revenue (latest FY) | $1.54M | $0 |
| Net income (latest FY) | $-258.76M | $-148.96M |
| Revenue growth (5y CAGR) | -26.9% | — |
| Net margin | -16748.0% | — |
| Return on equity | -49.1% | 41.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CLDX — free Open KLRA — freeFrequently asked questions
Which is bigger, CLDX or KLRA?
Kailera Therapeutics, Inc. is larger by market capitalization — $2.6B versus $2.3B.
Which grows faster, CLDX or KLRA?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.